Regarding the design of drugs or screening for small molecules that inhibit PUSs activity, while several studies have attempted to generate or find compounds to diminish DKC1 activity as potential anti-cancer treatments, very little progress has followed [291–293]. Here, DKC1 is linked to cancer.